Ceftriaxone Sodium for injection

Quick Detail

Package & Delivery Lead Time

Detailed Description

Ceftriaxone Sodium for injection Ingredient: Each vial contains ceftriaxone sodium equivalent to 1g of ceftriaxone. Each gram of ceftriaxone contains approximately82 mg (3.6mmol) of sodium. Specification: (0.25g/10ml*vial+5mlwater/box)*10boxes*20shrinks/ctn (500mg/7ml*50vials/box)*20boxes/ctn (500mg/7ml*10vials/box)*100boxes/ctn (500mg/10ml*vial+5mlwater/box)*10boxes*20shrinks/ctn (1g/7ml*10vials/box)*100boxes/ctn (1g/10ml*50vials/box)*20boxes/ctn (1g/10ml+10mlwater+5ml lidocaine(1%))/box*10boxes*20shrinks/ctn (1g/12ml+10mlwater)/box*10boxes*20shrinks/ctn Package We can do as ur requirement or can use our own package Remark: OEM available Or custom made Pharmaceutical form Powder for solution for injection (Powder for injection). White to pale yellow crystalline powder. Therapeutic indications: Ceftriaxone sodium is a broad-spectrum bactericidal cephalosporin antibiotic. Ceftriaxone is active in vitro against a wide range of Gram-positive and Gram-negative organisms, which include β-lactamase producing strains. Ceftriaxone is indicated in the treatment of the following infections either before the infecting organism has been identified or when known to be caused by bacteria of established sensitivity. Pneumonia Septicaemia Meningitis Skin and soft tissue infections Infections in neutropenic patients Gonorrhoea Peri-operative prophylaxis of infections associated with surgery Treatment may be started before the results of susceptibility tests are known. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Posology and method of administration Ceftriaxone may be administered by deep intramuscular injection, or as a slow intravenous injection, after reconstitution of the solution according to the directions given below. The dosage and mode of administration should be determined by the severity of the infection, susceptibility of the causative organism and the patient's condition. Under most circumstances a once-daily dose or, in the specified indications, one dose will give satisfactory therapeutic results. Diluents containing calcium, (e.g. Ringer's solution or Hartmann's solution), should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2). Intramuscular injection: 1g ceftriaxone should be dissolved in 3.5ml of 1% Lidocaine Injection BP. The solution should be administered by deep intramuscular injection. Doses greater than 1g should be divided and injected at more than one site. Intravenous injection: 1g ceftriaxone should be dissolved in 10ml of Water for Injections PhEur. The injection should be administered over at least 2-4 minutes, directly into the vein or via the tubing of an intravenous infusion. Adults and children 12 years and over: Standard therapeutic dosage: 1g once daily. Severe infections: 2-4 g daily, normally as a once daily dose. The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacterial eradication has been obtained. Acute, uncomplicated gonorrhoea: One dose of 250mg intramuscularly should be administered. Simultaneous administration of probenecid is not indicated. Peri-operative prophylaxis: Usually one dose of 1g given by intramuscular or slow intravenous injection. In colorectal surgery, 2g should be given intramuscularly (in divided doses at different injection sites), by slow intravenous injection or by slow intravenous infusion, in conjunction with a suitable agent against anaerobic bacteria. Elderly: These dosages do not require modification in elderly patients provided that renal and hepatic function are satisfactory (see below). In the neonate, the intravenous dose should be given over 60 minutes to reduce the displacement of bilirubin from albumin, thereby reducing the potential risk of bilirubin encephalopathy (see Special warning and precautions for use). Children under 12 years Standard therapeutic dosage: 20-50mg/kg body-weight once daily. Up to 80mg/kg body-weight daily may be given in severe infections, except in premature neonates where a daily dosage of 50mg/kg should not be exceeded. For children with body weights of 50kg or more, the usual dosage should be used. Doses of 50mg/kg or over should be given by slow intravenous infusion over at least 30 minutes. Doses greater than 80mg/kg body weight should be avoided because of the increased risk of biliary precipitates. Renal and hepatic impairment: In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided liver function is intact. Only in cases of pre-terminal renal failure (creatinine clearance <10ml per minute) should the daily dosage be limited to 2g or less. In patients with liver damage there is no need for the dosage to be reduced provided renal function is intact. In severe renal impairment accompanied by hepatic insufficiency, the plasma concentration of ceftriaxone should be determined at regular intervals and dosage adjusted. In patients undergoing dialysis, no additional supplementary dosage is required following the dialysis. Plasma concentrations should be monitored, however, to determine whether dosage adjustments are necessary, since the elimination rate in these patients may be reduced. Contraindications: Ceftriaxone is contraindicated in patients with known hypersensitivity to beta-lactam antibiotics. In patients hypersensitive to penicillin, the possibility of allergic cross-reactions should be borne in mind. Hyperbilirubinaemic newborns and preterm newborns should not be treated with ceftriaxone. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients. Ceftriaxone is contraindicated in: •premature newborns up to a corrected age of 41 weeks (weeks of gestation + weeks of life), •full-term newborns (up to 28 days of age) with o jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired o if they require (or are expected to require) IV calcium treatment, or calcium-containing infusions because of the risk of precipitation of ceftriaxone-calcium (see sections 4.4, 4.8 and 6.2). Contraindications of lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine is used as a solvent. Shelf Life: Unopened – Three years. For reconstituted solution, chemical and physical in-use stability has been demonstrated for 24 hours at 25oC and for four days at 2-8°C. From a microbiological point of view, once opened, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless reconstitution has taken place in controlled and validated aseptic conditions Storage: Unopened: Do not store above 25°C. Keep the vials in the outer carton. After reconstitution: Store at 2-8oC, see section 6.3 for complete storage instructions. Zhuhai Aoshun Medicine Co.,Ltd.

Basic Company Information

ZhuHai Aoshun Medicine Co.,Ltd

Company Advantage

Detail Company Introduction